{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:35:33Z","timestamp":1790847333874,"version":"4.1.0"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010949","name":"College of Medicine and Veterinary Medicine, University of Edinburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2019.00924","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:25:36Z","timestamp":1581380736000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":103,"title":["Management of Osteogenesis Imperfecta"],"prefix":"10.3389","volume":"10","author":[{"given":"Stuart H.","family":"Ralston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Gaston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ajmg.c.31532","article-title":"Pharmacological and biological therapeutic strategies for osteogenesis imperfecta","volume":"172","author":"Marom","year":"2016","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/ejhg.2015.81","article-title":"Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta","volume":"23","author":"Lindahl","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"BSR20182118","DOI":"10.1042\/BSR20182118","article-title":"A novel missense mutation in P4HB causes mild osteogenesis imperfecta","volume":"39","author":"Li","year":"2019","journal-title":"Biosci Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ajhg.2014.12.027","article-title":"Cole-Carpenter syndrome is caused by a heterozygous missense mutation in P4HB","volume":"96","author":"Rauch","year":"2015","journal-title":"Am J Hum Genet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11657-011-0054-z","article-title":"Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta","volume":"6","author":"Wekre","year":"2011","journal-title":"Arch Osteoporos"},{"key":"B8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","article-title":"Static and dynamic bone histomorphometry in children with osteogenesis imperfecta","volume":"26","author":"Rauch","year":"2000","journal-title":"Bone"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.bone.2004.02.023","article-title":"Bone turnover markers in patients with osteogenesis imperfecta","volume":"34","author":"Braga","year":"2004","journal-title":"Bone"},{"key":"B10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive transforming growth factor-\u03b2 signaling is a common mechanism in osteogenesis imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/jbmr.3617","article-title":"Effect of anti-TGF-\u03b2 treatment in a mouse model of severe osteogenesis imperfecta","volume":"34","author":"Tauer","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s00198-016-3501-2","article-title":"Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-\u03b1","volume":"27","author":"Brunetti","year":"2016","journal-title":"Osteoporos Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s002239900600","article-title":"The mineralization density of iliac crest bone from children with osteogenesis imperfecta","volume":"64","author":"Boyde","year":"1999","journal-title":"Calcif Tissue Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.bone.2009.10.037","article-title":"CRTAP deficiency leads to abnormally high bone matrix mineralization in a murine model and in children with osteogenesis imperfecta type VII","volume":"46","author":"Fratzl-Zelman","year":"2010","journal-title":"Bone"},{"key":"B15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00223-008-9113-x","article-title":"Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations","volume":"82","author":"Roschger","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"B16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.bone.2013.11.023","article-title":"Mineral particle size in children with osteogenesis imperfecta type I is not increased independently of specific collagen mutations","volume":"60","author":"Fratzl-Zelman","year":"2014","journal-title":"Bone"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1210\/jc.2016-1334","article-title":"Non-lethal type VIII osteogenesis imperfecta has elevated bone matrix mineralization","volume":"101","author":"Fratzl-Zelman","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.bone.2014.12.023","article-title":"Unique micro- and nano-scale mineralization pattern of human osteogenesis imperfecta type VI bone","volume":"73","author":"Fratzl-Zelman","year":"2015","journal-title":"Bone"},{"key":"B19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/JMDH.S113483","article-title":"Managing the patient with osteogenesis imperfecta: a multidisciplinary approach","volume":"10","author":"Marr","year":"2017","journal-title":"J Multidiscip Healthc."},{"key":"B20","first-page":"386","article-title":"Rehabilitation approaches to children with osteogenesis imperfecta: a ten-year experience","volume":"74","author":"Binder","year":"1993","journal-title":"Arch Phys Med Rehabil"},{"key":"B21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ajmg.1320450224","article-title":"Comprehensive rehabilitation of the child with osteogenesis imperfecta","volume":"45","author":"Binder","year":"1993","journal-title":"Am J Med Genet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(89)90277-8","article-title":"Side effects of pamidronate","volume":"334","author":"Gallacher","year":"1989","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1359\/jbmr.2003.18.4.610","article-title":"Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy","volume":"18","author":"Rauch","year":"2003","journal-title":"J Bone Miner Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.bone.2006.04.004","article-title":"Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment","volume":"39","author":"Land","year":"2006","journal-title":"Bone"},{"key":"B26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta","volume":"21","author":"DiMeglio","year":"2006","journal-title":"J Bone Miner Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"CD005088","DOI":"10.1002\/14651858.CD005088.pub4","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/jbmr.2920","article-title":"Fracture rates and fracture sites in patients with osteogenesis imperfecta: a nationwide register-based cohort study","volume":"32","author":"Folkestad","year":"2017","journal-title":"J Bone Miner Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1359\/JBMR.051015","article-title":"Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial","volume":"21","author":"Chevrel","year":"2006","journal-title":"J Bone Miner Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1359\/jbmr.090712","article-title":"A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta","volume":"25","author":"Bishop","year":"2010","journal-title":"J Bone Miner Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1359\/jbmr.090213","article-title":"Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"24","author":"Rauch","year":"2009","journal-title":"J Bone Miner Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"J Bone Miner Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00431-006-0399-2","article-title":"Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial","volume":"166","author":"Kok","year":"2007","journal-title":"Eur J Pediatr"},{"key":"B37","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2015","journal-title":"J Bone Miner Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone"},{"key":"B39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S8756-3282(01)00485-9","article-title":"Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women","volume":"29","author":"Roschger","year":"2001","journal-title":"Bone"},{"key":"B40","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"key":"B41","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect\u2013a first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"B42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","article-title":"Two years' experience with denosumab for children with osteogenesis imperfecta type VI","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"B43","first-page":"76","article-title":"Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI","volume":"18","author":"Trejo","year":"2018","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"B44","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/apa.14154","article-title":"Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings","volume":"107","author":"Li","year":"2018","journal-title":"Acta Paediatr"},{"key":"B45","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00223-019-00563-8","article-title":"Long-term effects of teriparatide followed by antiresorptive therapy on clinical outcomes in patients with severe spinal osteoporosis","volume":"105","author":"Oswald","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"B46","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2017","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J Clin Invest"},{"key":"B48","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","article-title":"Teriparatide treatment in adult patients with osteogenesis imperfecta type I","volume":"93","author":"Gatti","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"B49","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Dev Cell."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/jbmr.2152","article-title":"Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody","volume":"29","author":"Ominsky","year":"2014","journal-title":"J Bone Miner Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"key":"B53","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/6529","article-title":"Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta","volume":"5","author":"Horwitz","year":"1999","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1182\/blood.V97.5.1227","article-title":"Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta","volume":"97","author":"Horwitz","year":"2001","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"8932","DOI":"10.1073\/pnas.132252399","article-title":"Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone","volume":"99","author":"Horwitz","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B56","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/sj.mt.6300339","article-title":"Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta","volume":"16","author":"Chamberlain","year":"2008","journal-title":"Mol Ther"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1126\/science.1088757","article-title":"Gene targeting in stem cells from individuals with osteogenesis imperfecta","volume":"303","author":"Chamberlain","year":"2004","journal-title":"Science"},{"key":"B58","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.3928\/01477447-20161006-04","article-title":"Challenges of fracture management for adults with osteogenesis imperfecta","volume":"40","author":"Gil","year":"2017","journal-title":"Orthopedics"},{"key":"B60","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2106\/00004623-195941080-00001","article-title":"Fragmentation, realignment, and intramedullary rod fixation of deformities of the long bones in children: a ten year appraisal","author":"Sofield","year":"1959","journal-title":"J Bone Joint Surg Am"},{"key":"B61","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/BPO.0b013e31821bfb50","article-title":"Experience with the Fassier-Duval telescopic rod: first 24 consecutive cases with a minimum of 1-year follow-up","volume":"31","author":"Birke","year":"2011","journal-title":"J Pediatr Orthop"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.2106\/JBJS.J.01893","article-title":"Use of the Sheffield telescopic intramedullary rod system for the management of osteogenesis imperfecta: clinical outcomes at an average follow-up of nineteen years","volume":"93","author":"Nicolaou","year":"2011","journal-title":"J Bone Joint Surg Am."},{"key":"B63","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/01202412-200511000-00013","article-title":"Non-union in osteogenesis imperfecta","volume":"14","author":"Agarwal","year":"2005","journal-title":"J Pediatr Orthop B."},{"key":"B64","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/BPO.0000000000000729","article-title":"Functional outcome of humeral rodding in children with osteogenesis imperfecta","volume":"38","author":"Ashby","year":"2018","journal-title":"J Pediatr Orthop"},{"key":"B65","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/BPO.0000000000000724","article-title":"Functional outcome of forearm rodding in children with osteogenesis imperfecta","volume":"38","author":"Ashby","year":"2018","journal-title":"J Pediatr Orthop"},{"key":"B66","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/BPO.0000000000000856","article-title":"Initial experience with percutaneous IM rodding of the humeri in children with osteogenesis imperfecta","volume":"38","author":"Grossman","year":"2018","journal-title":"J Pediatr Orthop"},{"key":"B67","doi-asserted-by":"publisher","first-page":"E488","DOI":"10.1097\/BRS.0b013e31811ec2d9","article-title":"Correlation of scoliotic curvature with Z-score bone mineral density and body mass index in patients with osteogenesis imperfecta","volume":"32","author":"Watanabe","year":"2007","journal-title":"Spine (Phila Pa 1976)"},{"key":"B68","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1302\/0301-620X.64B1.7068718","article-title":"Scoliosis associated with osteogenesis imperfecta","volume":"64","author":"Yong-Hing","year":"1982","journal-title":"J Bone Joint Surg Br."},{"key":"B69","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2106\/JBJS.L.01596","article-title":"Behavior of scoliosis during growth in children with osteogenesis imperfecta","volume":"96","author":"Anissipour","year":"2014","journal-title":"J Bone Joint Surg Am"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/00007632-199908150-00008","article-title":"Spinal deformity, pulmonary compromise, and quality of life in osteogenesis imperfecta","volume":"24","author":"Widmann","year":"1999","journal-title":"Spine (Phila Pa 1976)"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1148\/rg.327125716","article-title":"Craniospinal abnormalities and neurologic complications of osteogenesis imperfecta: imaging overview","volume":"32","author":"Khandanpour","year":"2012","journal-title":"Radiographics."},{"key":"B72","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/BPO.0b013e31822889c9","article-title":"The incidence of spondylolysis and spondylolisthesis in children with osteogenesis imperfecta","volume":"31","author":"Hatz","year":"2011","journal-title":"J Pediatr Orthop."},{"key":"B73","first-page":"943","article-title":"The spine in osteogenesis imperfecta","volume-title":"The Pediatric Spine: Principles and Practice","author":"Lubicky","year":"1993"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00924\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:25:40Z","timestamp":1581380740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00924\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":73,"alternative-id":["10.3389\/fendo.2019.00924"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2019.00924","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]},"article-number":"924"}}